dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Matute Blanch, Clara |
dc.contributor.author | Osman, Mohamoud |
dc.contributor.author | Costa Riu, Carme |
dc.contributor.author | Pinteac, Rucsanda |
dc.contributor.author | Miró Cau, Berta |
dc.contributor.author | Sánchez Pla, Alex |
dc.contributor.author | Brito, Veronica Ines |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Comabella Lopez, Manuel |
dc.contributor.author | Fissolo, Nicolás Miguel |
dc.date.accessioned | 2022-06-16T08:02:45Z |
dc.date.available | 2022-06-16T08:02:45Z |
dc.date.issued | 2021-03 |
dc.identifier.citation | Fissolo N, Matute-Blanch C, Osman M, Costa C, Pinteac R, Miró B, et al. CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021 Mar;8(2):e941. |
dc.identifier.issn | 2332-7812 |
dc.identifier.uri | https://hdl.handle.net/11351/7703 |
dc.description | Esclerosi múltiple; SERPINA3 |
dc.description.sponsorship | This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; grant number PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS. |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Neurology neuroimmunology & neuroinflammation.;8(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Marcadors bioquímics |
dc.subject | Esclerosi múltiple - Diagnòstic |
dc.subject | Enzims proteolítics - Inhibidors |
dc.subject.mesh | Multiple Sclerosis, Chronic Progressive |
dc.subject.mesh | Serpins |
dc.subject.mesh | Biomarkers |
dc.title | CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/NXI.0000000000000941 |
dc.subject.decs | esclerosis múltiple crónica progresiva |
dc.subject.decs | serpinas |
dc.subject.decs | biomarcadores |
dc.relation.publishversion | https://doi.org/10.1212/NXI.0000000000000941 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Fissolo N, Matute-Blanch C, Costa C, Pinteac R, Brito V, Comabella Lopez M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Osman M] Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark. [Miró B] Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Sanchez A] Unitat d'Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Genetics, Microbiology and Statistics Department, Universitat de Barcelona, Spain. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Center for Multiple Sclerosis, St. Michael’s Hospital, University of Toronto, ON, Canada |
dc.identifier.pmid | 33436375 |
dc.identifier.wos | 000656639200009 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0015%2F0004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |